Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection

PLoS Pathogens

Volumn 13, Issue 7, 2017, Pages

  Kijak, Gustavo H ^a,b,m   Sanders Buell, Eric ^a,b   Chenine, Agnes Laurence ^a,b   Eller, Michael A ^a,b   Goonetilleke, Nilu ^c   Thomas, Rasmi ^a,b   Leviyang, Sivan ^d   Harbolick, Elizabeth A ^a,b   Bose, Meera ^a,b   Pham, Phuc ^a,b   Oropeza, Celina ^a,b   Poltavee, Kultida ^a,b   O’Sullivan, Anne Marie ^a,b   Billings, Erik ^a,b   Merbah, Melanie ^a,b   Costanzo, Margaret C ^a,b   Warren, Joanna A ^c   Slike, Bonnie ^a,b   Li, Hui ^e   Peachman, Kristina K ^a,b   Fischer, Will ^f   Gao, Feng ^g   Cicala, Claudia ^h   Arthos, James ^h   Eller, Leigh A ^a,b   O’Connell, Robert J ⁱ   Sinei, Samuel ^j   Maganga, Lucas ^k   Kibuuka, Hannah ^l   Nitayaphan, Sorachai ⁱ   Rao, Mangala ^a   Marovich, Mary A ^h   Krebs, Shelly J ^a,b   Rolland, Morgane ^a,b   Korber, Bette T ^f   Shaw, George M ^e   Michael, Nelson L ^a   Robb, Merlin L ^a,b   Tovanabutra, Sodsai ^a,b   Kim, Jerome H ^a,n   more..

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f LOS ALAMOS NATIONAL LABORATORY   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^j Walter Reed Project   (Kenya)

^k Mbeya Medical Research Programme   (Tanzania)

^l Makerere University   (Uganda)

^m GLAXOSMITHKLINE   (United States)

ⁿ International Vaccine Institute   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; RETINOIC ACID; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CELL LINEAGE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; RISK FACTOR; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; VIRUS TRANSMISSION; YOUNG ADULT; ADOLESCENT; CLASSIFICATION; COHORT ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PHYSIOLOGY; TRANSMISSION; VIROLOGY;

ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; YOUNG ADULT;

EID: 85026886364     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006510     Document Type: Article

References (86)

1. (UNAIDS) JUNPoHA. The gap report. Geneva, Switzerland2014.
2. Palella FJ, Jr.Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138(8):620–6. 12693883.
3. Fauci AS, Marston HD, Focusing to achieve a world without AIDS. JAMA. 2015;313(4):357–8. doi: 10.1001/jama.2014.17454 25626032.
4. Shaw GM, Hunter E, HIV transmission. Cold Spring Harb Perspect Med. 2012;2(11). doi: 10.1101/cshperspect.a006965 23043157; PubMed Central PMCID: PMCPMC3543106.
5. Robb ML, Eller LA, Kibuuka H, Rono K, Maganga L, Nitayaphan S, et al. Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. N Engl J Med. 2016;374(22):2120–30. doi: 10.1056/NEJMoa1508952 27192360; PubMed Central PMCID: PMCPMC5111628.
6. Haase AT, Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med. 2011;62:127–39. doi: 10.1146/annurev-med-080709-124959 21054171.
7. Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med. 1991;324(14):954–60. doi: 10.1056/NEJM199104043241404 1900576.
8. Daar ES, Moudgil T, Meyer RD, Ho DD, Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991;324(14):961–4. doi: 10.1056/NEJM199104043241405 1823118.
9. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200(6):749–59. doi: 10.1084/jem.20040874 15365096; PubMed Central PMCID: PMCPMC2211962.
10. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200(6):761–70. doi: 10.1084/jem.20041196 15365095; PubMed Central PMCID: PMCPMC2211967.
11. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83(8):3719–33. doi: 10.1128/JVI.01844-08 19176632; PubMed Central PMCID: PMCPMC2663284.
12. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med. 2009;206(6):1253–72. doi: 10.1084/jem.20090365 19487423; PubMed Central PMCID: PMCPMC2715063.
13. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68(7):4650–5. 8207839; PubMed Central PMCID: PMCPMC236393.
14. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422(6929):307–12. doi: 10.1038/nature01470 12646921.
15. Palmer S, Josefsson L, Coffin JM, HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med. 2011;270(6):550–60. doi: 10.1111/j.1365-2796.2011.02457.x 21929712.
16. Siliciano JM, Siliciano RF, The Remarkable Stability of the Latent Reservoir for HIV-1 in Resting Memory CD4+ T Cells. J Infect Dis. 2015;212(9):1345–7. doi: 10.1093/infdis/jiv219 25877551.
17. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512(7512):74–7. doi: 10.1038/nature13594 25042999; PubMed Central PMCID: PMCPMC4126858.
18. Ananworanich J, Chomont N, Eller LA, Kroon E, Tovanabutra S, Bose M, et al. HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART. EBioMedicine. 2016;11:68–72. doi: 10.1016/j.ebiom.2016.07.024 27460436; PubMed Central PMCID: PMCPMC5049918.
19. Picker LJ, Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol. 2006;18(4):399–405. doi: 10.1016/j.coi.2006.05.001 16753288.
20. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–54. 9182471.
21. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;105(21):7552–7. doi: 10.1073/pnas.0802203105 18490657; PubMed Central PMCID: PMCPMC2387184.
22. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol. 2009;83(8):3556–67. doi: 10.1128/JVI.02132-08 19193811; PubMed Central PMCID: PMCPMC2663249.
23. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 2009;5(1):e1000274. doi: 10.1371/journal.ppat.1000274 19165325; PubMed Central PMCID: PMCPMC2621345.
24. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206(6):1273–89. doi: 10.1084/jem.20090378 19487424; PubMed Central PMCID: PMCPMC2715054.
25. Nofemela A, Bandawe G, Thebus R, Marais J, Wood N, Hoffmann O, et al. Defining the human immunodeficiency virus type 1 transmission genetic bottleneck in a region with multiple circulating subtypes and recombinant forms. Virology. 2011;415(2):107–13. doi: 10.1016/j.virol.2010.12.027 21531432.
26. Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J, et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science. 2014;345(6193):1254031. doi: 10.1126/science.1254031 25013080; PubMed Central PMCID: PMCPMC4289910.
27. Tully DC, Ogilvie CB, Batorsky RE, Bean DJ, Power KA, Ghebremichael M, et al. Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus. PLoS Pathog.2016;12(5):e1005619. doi: 10.1371/journal.ppat.1005619 27163788; PubMed Central PMCID: PMCPMC4862634.
28. Herbeck JT, Rolland M, Liu Y, McLaughlin S, McNevin J, Zhao H, et al. Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol. 2011;85(15):7523–34. doi: 10.1128/JVI.02697-10 21593162; PubMed Central PMCID: PMCPMC3147913.
29. Liu MK, Hawkins N, Ritchie AJ, Ganusov VV, Whale V, Brackenridge S, et al. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest. 2013;123(1):380–93. doi: 10.1172/JCI65330 23221345; PubMed Central PMCID: PMCPMC3533301.
30. Fischer W, Ganusov VV, Giorgi EE, Hraber PT, Keele BF, Leitner T, et al. Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One. 2010;5(8):e12303. doi: 10.1371/journal.pone.0012303 20808830; PubMed Central PMCID: PMCPMC2924888.
31. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, et al. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog. 2012;8(3):e1002529. doi: 10.1371/journal.ppat.1002529 22412369; PubMed Central PMCID: PMCPMC3297584.
32. Fennessey CM, Keele BF, Using nonhuman primates to model HIV transmission. Curr Opin HIV AIDS. 2013;8(4):280–7. doi: 10.1097/COH.0b013e328361cfff 23666391; PubMed Central PMCID: PMCPMC3999893.
33. Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol. 2010;84(12):6241–7. doi: 10.1128/JVI.00077-10 20375173; PubMed Central PMCID: PMCPMC2876625.
34. Ndhlovu ZM, Kamya P, Mewalal N, Kloverpris HN, Nkosi T, Pretorius K, et al. Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point. Immunity. 2015;43(3):591–604. doi: 10.1016/j.immuni.2015.08.012 26362266; PubMed Central PMCID: PMCPMC4575777.
35. Kijak GH, Sanders-Buell E, Harbolick EA, Pham P, Chenine AL, Eller LA, et al. Targeted deep sequencing of HIV-1 using the IonTorrentPGM platform. J Virol Methods. 2014;205:7–16. doi: 10.1016/j.jviromet.2014.04.017 24797459; PubMed Central PMCID: PMCPMC4219931.
36. Eller MA, Goonetilleke N, Tassaneetrithep B, Eller LA, Costanzo MC, Johnson S, et al. Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. J Virol. 2016;90(8):4005–16. doi: 10.1128/JVI.02785-15 26842474; PubMed Central PMCID: PMCPMC4810544.
37. Boutwell CL, Rolland MM, Herbeck JT, Mullins JI, Allen TM, Viral evolution and escape during acute HIV-1 infection. J Infect Dis. 2010;202Suppl 2:S309–14. doi: 10.1086/655653 20846038; PubMed Central PMCID: PMCPMC2945609.
38. Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, Rousseau C, et al. Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol. 2008;82(17):8548–59. doi: 10.1128/JVI.00580-08 18596105; PubMed Central PMCID: PMCPMC2519667.
39. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, et al. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog. 2009;5(5):e1000414. doi: 10.1371/journal.ppat.1000414 19424423; PubMed Central PMCID: PMCPMC2671846.
40. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS, Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol. 2004;337(3):585–96. doi: 10.1016/j.jmb.2004.01.046 15019779.
41. Liddament MT, Brown WL, Schumacher AJ, Harris RS, APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol. 2004;14(15):1385–91. doi: 10.1016/j.cub.2004.06.050 15296757.
42. Ganusov VV, De Boer RJ, Estimating Costs and Benefits of CTL Escape Mutations in SIV/HIV Infection. PLoS Comput Biol. 2006;2(3):e24. doi: 10.1371/journal.pcbi.0020024 16604188; PubMed Central PMCID: PMCPMC1420660.
43. Fernandez CS, Stratov I, De Rose R, Walsh K, Dale CJ, Smith MZ, et al. Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol. 2005;79(9):5721–31. doi: 10.1128/JVI.79.9.5721-5731.2005 15827187; PubMed Central PMCID: PMCPMC1082732.
44. Asquith B, Zhang Y, Mosley AJ, de Lara CM, Wallace DL, Worth A, et al. In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. Proc Natl Acad Sci U S A. 2007;104(19):8035–40. doi: 10.1073/pnas.0608832104 17483473; PubMed Central PMCID: PMCPMC1861853.
45. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A, Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87–103. doi: 10.1038/nri3787 25614319.
46. Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferott K, Aasa-Chapman MM, et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology. 2013;10:146. doi: 10.1186/1742-4690-10-146 24299076; PubMed Central PMCID: PMCPMC3907080.
47. Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-Ngern Y, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014;10(12):e1004543. doi: 10.1371/journal.ppat.1004543 25503054; PubMed Central PMCID: PMCPMC4263756.
48. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008;9(3):301–9. doi: 10.1038/ni1566 18264102.
49. Ritchie AJ, Cai F, Smith NM, Chen S, Song H, Brackenridge S, et al. Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. Retrovirology. 2014;11:69. doi: 10.1186/s12977-014-0069-9 25212771; PubMed Central PMCID: PMCPMC4180588.
50. Del Prete GQ, Park H, Fennessey CM, Reid C, Lipkey L, Newman L, et al. Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events. J Virol. 2014;88(14):8077–90. doi: 10.1128/JVI.01026-14 24807714; PubMed Central PMCID: PMCPMC4097795.
51. Li H, Blair L, Chen Y, Learn G, Pfafferott K, John M, et al. Molecular mechanisms of HIV type 1 prophylaxis failure revealed by single-genome sequencing. J Infect Dis. 2013;208(10):1598–603. doi: 10.1093/infdis/jit485 24023257; PubMed Central PMCID: PMCPMC3805246.
52. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature. 2014;511(7511):601–5. doi: 10.1038/nature13554 25043006; PubMed Central PMCID: PMCPMC4418221.
53. Vanderford TH, Bleckwehl C, Engram JC, Dunham RM, Klatt NR, Feinberg MB, et al. Viral CTL escape mutants are generated in lymph nodes and subsequently become fixed in plasma and rectal mucosa during acute SIV infection of macaques. PLoS Pathog. 2011;7(5):e1002048. doi: 10.1371/journal.ppat.1002048 21625590; PubMed Central PMCID: PMCPMC3098234.
54. Davenport MP, Ribeiro RM, Perelson AS, Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol. 2004;78(18):10096–103. doi: 10.1128/JVI.78.18.10096-10103.2004 15331742; PubMed Central PMCID: PMCPMC515020.
55. Asquith B, Edwards CT, Lipsitch M, McLean AR, Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biol. 2006;4(4):e90. doi: 10.1371/journal.pbio.0040090 16515366; PubMed Central PMCID: PMCPMC1395353.
56. Liu Y, McNevin J, Cao J, Zhao H, Genowati I, Wong K, et al. Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol. 2006;80(19):9519–29. doi: 10.1128/JVI.00575-06 16973556; PubMed Central PMCID: PMCPMC1617227.
57. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 1997;3(2):205–11. 9018240.
58. Sunshine JE, Larsen BB, Maust B, Casey E, Deng W, Chen L, et al. Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection. J Virol. 2015;89(20):10303–18. doi: 10.1128/JVI.01876-15 26223634; PubMed Central PMCID: PMCPMC4580195.
59. Ladell K, Hashimoto M, Iglesias MC, Wilmann PG, McLaren JE, Gras S, et al. A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. Immunity. 2013;38(3):425–36. doi: 10.1016/j.immuni.2012.11.021 23521884.
60. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med. 2004;10(3):282–9. doi: 10.1038/nm992 14770175.
61. Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, et al. HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nat Med. 2015;21(10):1139–41. doi: 10.1038/nm.3932 26322580; PubMed Central PMCID: PMCPMC4598284.
62. Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, Khoza T, et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015;21(11):1332–6. doi: 10.1038/nm.3963 26457756; PubMed Central PMCID: PMCPMC4637988.
63. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R, Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci U S A. 2011;108(50):20166–71. doi: 10.1073/pnas.1110064108 22135472; PubMed Central PMCID: PMCPMC3250168.
64. Konrad BP, Taylor D, Conway JM, Ogilvie GS, Coombs D, On the duration of the period between exposure to HIV and detectable infection. Epidemics. 2017. doi: 10.1016/j.epidem.2017.03.002 28365331.
65. Anderson JA, Ping LH, Dibben O, Jabara CB, Arney L, Kincer L, et al. HIV-1 Populations in Semen Arise through Multiple Mechanisms. PLoS Pathog. 2010;6(8):e1001053. doi: 10.1371/journal.ppat.1001053 20808902; PubMed Central PMCID: PMCPMC2924360.
66. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 2011;7(9):e1002209. doi: 10.1371/journal.ppat.1002209 21980282; PubMed Central PMCID: PMCPMC3182927.
67. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, et al. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog. 2010;6(5):e1000890. doi: 10.1371/journal.ppat.1000890 20485520; PubMed Central PMCID: PMCPMC2869329.
68. Masharsky AE, Dukhovlinova EN, Verevochkin SV, Toussova OV, Skochilov RV, Anderson JA, et al. A substantial transmission bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg, Russia. J Infect Dis. 2010;201(11):1697–702. doi: 10.1086/652702 20423223.
69. Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med. 2009;206(5):1117–34. doi: 10.1084/jem.20082831 19414559; PubMed Central PMCID: PMCPMC2715022.
70. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17(13):1871–9. doi: 10.1097/01.aids.0000076308.76477.b8 12960819.
71. Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, deCamp AC, et al. Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comput Biol. 2015;11(2):e1003973. doi: 10.1371/journal.pcbi.1003973 25646817; PubMed Central PMCID: PMCPMC4315437.
72. Larsen BB, Chen L, Maust BS, Kim M, Zhao H, Deng W, et al. Improved detection of rare HIV-1 variants using 454 pyrosequencing. PLoS One. 2013;8(10):e76502. doi: 10.1371/journal.pone.0076502 24098517; PubMed Central PMCID: PMCPMC3788733.
73. Giorgi EE, Funkhouser B, Athreya G, Perelson AS, Korber BT, Bhattacharya T, Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics. 2010;11:532. doi: 10.1186/1471-2105-11-532 20973976; PubMed Central PMCID: PMCPMC2975664.
74. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics. 2012;28(12):1647–9. doi: 10.1093/bioinformatics/bts199 22543367; PubMed Central PMCID: PMCPMC3371832.
75. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S, MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013;30(12):2725–9. doi: 10.1093/molbev/mst197 24132122; PubMed Central PMCID: PMCPMC3840312.
76. Korber B, Foley B, Kuiken C, Pillai S, Sodroski J, Korber B, Kuiken C, Foley B, Hahn B, McCutchan F, Mellors J, Numbering Positions in HIV Relative to HXB2CG. In: et al., editors. Human Retroviruses and AIDS. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 1998. p. III-102-11.
77. Lassmann T, Hayashizaki Y, Daub CO, SAMStat: monitoring biases in next generation sequencing data. Bioinformatics. 2011;27(1):130–1. doi: 10.1093/bioinformatics/btq614 21088025; PubMed Central PMCID: PMCPMC3008642.
78. Kijak GH, Pham P, Sanders-Buell E, Harbolick EA, Eller LA, Robb ML, et al. Nautilus: a bioinformatics package for the analysis of HIV type 1 targeted deep sequencing data. AIDS Res Hum Retroviruses. 2013;29(10):1361–4. Epub 2013/07/03. doi: 10.1089/AID.2013.0175 23809062; PubMed Central PMCID: PMC3785804.
79. Milne I, Stephen G, Bayer M, Cock PJ, Pritchard L, Cardle L, et al. Using Tablet for visual exploration of second-generation sequencing data. Brief Bioinform. 2013;14(2):193–202. Epub 2012/03/27. doi: 10.1093/bib/bbs012 22445902.
80. Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Kosakovsky Pond SL, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016;530(7588):51–6. doi: 10.1038/nature16933 26814962; PubMed Central PMCID: PMCPMC4865637.
81. Chenine AL, Wieczorek L, Sanders-Buell E, Wesberry M, Towle T, Pillis DM, et al. Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone. PLoS One. 2013;8(11):e76104. doi: 10.1371/journal.pone.0076104 24312165; PubMed Central PMCID: PMCPMC3843658.
82. Weber K, Bartsch U, Stocking C, Fehse B, A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther. 2008;16(4):698–706. doi: 10.1038/mt.2008.6 18362927.
83. Kim JH, Pitisuttithum P, Kamboonruang C, Chuenchitra T, Mascola J, Frankel SS, et al. Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1. AIDS Res Hum Retroviruses. 2003;19(9):807–16. doi: 10.1089/088922203769232601 14585211.
84. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012;206(3):431–41. doi: 10.1093/infdis/jis367 22634875; PubMed Central PMCID: PMCPMC3392187.
85. Lazarovits AI, Moscicki RA, Kurnick JT, Camerini D, Bhan AK, Baird LG, et al. Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol. 1984;133(4):1857–62. 6088627.
86. Prentice HA, Ehrenberg PK, Baldwin KM, Geretz A, Andrews C, Nitayaphan S, et al. HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. Immunogenetics. 2014;66(5):299–310. doi: 10.1007/s00251-014-0765-6 24682434.